Tag
Pharmaceuticals
70 articles
The Indian pharmaceutical sector continues to see both expansion and regulatory activity. Aurobindo Pharma received USFDA approval for Perampanel tablets, targeting a $67 million market, while Granules India incorporated a Brazilian subsidiary to expand its presence in South America. Meanwhile, Emcure Pharmaceuticals faces a ₹57.74 crore income tax penalty, highlighting ongoing regulatory scrutiny. Acquisitions are also reshaping the landscape, with Aurobindo Pharma's Apitoria completing deals for A1 Biochem's CRO business and A1 Biochem Labs LLC, creating a broader contract research and development manufacturing organization. These developments suggest a dynamic environment for Indian pharmaceutical companies, balancing growth opportunities with regulatory challenges and strategic consolidation.
Aurobindo Pharma Receives USFDA Approval for Perampanel
Aurobindo Pharma received USFDA final approval for Perampanel Tablets across six dosage strengths for epilepsy treatment.
The product has an estimated market size of $67 million and will be manufactur
Lifevision Healthcare Expands Third-Party Pharma Manufacturing
Lifevision Healthcare, founded in 2010, announces expanded third‑party manufacturing services for tablets, capsules, syrups and other dosage forms.
The firm operates a manufacturing unit in Baddi, Him
FICCI-Lilly Bharat Award Grants Rs 7 Cr
Union Health Minister Jagat Prakash Nadda urges life‑sciences industry to prioritize patient‑centric innovation, citing Ayushman Bharat PM‑JAY coverage.
The inaugural Bharat Life Sciences Award, organ
Emcure Receives ₹577 Crore Income Tax Penalty
Emcure Pharmaceuticals discloses regulatory orders from the Income-tax Department imposing an aggregate penalty of ₹57.74 crore.
The penalty covers financial years 2014-15 to 2020-21 (assessment years
Granules India Incorporates Brazilian Pharma Subsidiary Triton
Granules India incorporated a wholly-owned foreign subsidiary named Triton Farmaceutica do Brasil Ltda in Brazil.
The new subsidiary will manufacture, promote, sell, and distribute pharmaceuticals and
Aurobindo Pharma Subsidiary Completes A1 Biochem Acquisition
Aurobindo Pharma's subsidiary Apitoria completed acquisition of A1 Biochem's Contract Research Services business.
Apitoria now holds 80% stake in A1 Biochem Labs India and 20% is held by former promot
Aurobindo Pharma Subsidiary Acquires A1 Biochem Labs LLC
Aurobindo Pharma's subsidiary Apitoria completes acquisition of A1 Biochem Labs LLC for USD 15.247 million in cash.
The acquisition expands Aurobindo's API business into contract research, creating a
Department of Pharmaceuticals Commences Special Campaign 6
Department of Pharmaceuticals launches Special Campaign 6 focusing on e-waste management and pendency liquidation from October 2-31, 2026.
Campaign targets 12,208 cleanliness drives and scientific dis
Haleos Labs 20th AGM All Resolutions Passed
Haleos Labs held its 20th AGM on September 30, 2026, via video conference with 58 shareholders attending.
All eight proposed resolutions, including dividend declaration and director appointments, were
Piramal Pharma's Bayer Distribution Pact Expiry
Piramal Pharma discloses non-renewal of its sales and distribution services arrangement with Bayer Pharmaceuticals, effective December 31, 2026.
The expiring arrangement contributed less than 5% of co
Syncom Formulations Appoints Bankdas as Managing and Whole-Time Directors
Syncom Formulations appointed Shri Rahul Vijay Bankda as Managing Director and Smt. Rinki Ankit Bankda as Whole-Time Director, effective August 12, 2026.
Smt. Ruchi Jindal was re-appointed as Woman In
Syncom Formulations AGM Approves Dividend, Director Appointments
Shareholders approved 10% dividend of ₹0.10 per share for FY2026 at 38th AGM.
Members reappointed Ankit Bankda and confirmed Rahul Bankda as Managing Director.
AGM ratified FY2027 cost auditor remuner
Zota Health Q2 Store Count Rises to 2840
Zota Health Care reports Q2FY27 store count update with total stores increasing to 2840 from 2825 in previous quarter.
Company-operated COCO stores grew to 1859 while franchise-operated FOFO stores re
Department of Pharmaceuticals Organizes Cleanliness Drive
Department of Pharmaceuticals conducted one-hour voluntary Shramdaan cleanliness drive near Shastri Bhawan, New Delhi.
Secretary Manoj Joshi led the initiative, administered Swachhata pledge, and plan
Viyash Completes €16.98M BioForLife Italia Acquisition
Viyash Scientific's subsidiary Alivira completes 100% acquisition of BioForLife Italia S.r.l. for a total consideration of €16.976 million.
Base purchase consideration is €15.0 million with an additio
Mangalam Drugs Appoints 78-Year-Old Independent Director
Mangalam Drugs seeks shareholder approval via postal ballot for appointing Prabhakar Zavar as Non-Executive Independent Director for five years.
The resolution is a special requirement under SEBI LODR
Hikal Ltd Executive Chairman Cessation and Director Resignation
Hikal Ltd's Executive Chairman Jai Hiremath ceased office effective October 1, 2026 after nearly four decades of leadership.
Non-Executive Director Sugandha Hiremath resigned effective September 30, 2
Balaji Amines Receives FDA Warning Letter
Balaji Amines discloses receipt of a warning letter from the Food & Drug Administration, Pune dated January 10, 2025.
The letter was issued due to a customer's unauthorized resale of technical-grade P
Dishman Carbogen Amcis 19th AGM Voting Results
Dishman Carbogen Amcis held its 19th AGM on 30th September 2026 via video conferencing for 35 minutes.
All five proposed ordinary resolutions were passed with near-unanimous approval from shareholders
Alpa Laboratories 38th AGM Proceedings September 2026
Held 38th AGM via video conference on September 30, 2026, to transact ordinary and special business items.
Approved reappointment of Paresh Chawla as Managing Director and Radhika Biyani as Independen
Ortin Global 39th AGM Held on September 30, 2026
Ortin Global held its 39th Annual General Meeting virtually on September 30, 2026, with 39 members in attendance.
Five resolutions were considered including adoption of FY26 financial statements and d
Gujarat Themis Biosyn 45th AGM Voting Results
Gujarat Themis Biosyn disclosed scrutinizer report and voting results from its 45th Annual General Meeting held on September 30, 2026.
All resolutions passed with overwhelming approval except Resoluti
DoP Announces ₹50 Crore Pharma Discovery Track
Department of Pharmaceuticals launches New Discovery track under PRIP Scheme offering up to ₹50 crore financial assistance per project for drug discovery startups and MSMEs.
The scheme requires minimu
India Approves ₹1,600 Crore for 41 Pharma-MedTech Projects
India's Department of Pharmaceuticals approved ₹1,600 crore for 41 R&D projects under the PRIP scheme's first round.
The funding is expected to catalyze ₹4,620 crore in total R&D investment, including
Pharmaceuticals Department Observes Swachhata Pakhwada 2026
Department of Pharmaceuticals conducted Swachhata Pakhwada cleanliness drive from September 1-15, 2026 across offices, NIPERs and PSUs.
Secretary Manoj Joshi administered Swachhata pledge; Joint Secre
India's Pharma PLI Schemes Achieve ₹55,954 Crore Investment
Government reports PLI schemes for pharma, bulk drugs, and medical devices have attracted ₹55,954 crore investment, exceeding targets.
Bulk Drugs PLI achieved ₹5,210 crore investment with 39 projects
Department of Pharmaceuticals Special Campaign 6.0
Department of Pharmaceuticals launches Special Campaign 6.0 from October 2-31, 2026 focusing on e-waste management and grievance redressal.
Campaign involves NPPA, seven NIPERs, PMBI, and three PSUs t
PLI Scheme for Bulk Drugs: Five Projects Commissioned
Five greenfield projects commissioned under PLI Scheme for Bulk Drugs, strengthening domestic API, KSM, and DI manufacturing.
Projects include Lyfius Pharma's ₹2,270cr Penicillin G plant and Kinvan's
Piramal Pharma Appoints Viral Gandhi as CTO
Piramal Pharma appointed Mr. Viral Gandhi as Chief Technology Officer effective 1st October 2026.
The appointment was approved by the Board based on Nomination and Remuneration Committee recommendatio
Dishman Carbogen Amcis 19th AGM Voting Results
Scrutinizer's report confirms all four resolutions passed at the 19th AGM held via video conference on September 30, 2026.
Shareholders approved audited standalone and consolidated financial statement
DoP Announces ₹50 Crore Pharma Innovation Funding Track
Department of Pharmaceuticals launches New Discovery track under PRIP Scheme offering up to ₹50 crore funding for pharma startups and MSMEs.
Scheme requires minimum 25% co-funding from institutional i
Innova Captab 22nd AGM Approves Director Reappointments
Innova Captab held its 22nd AGM on 30th September 2026 via video conference to transact ordinary and special business.
Shareholders voted on 10 resolutions including adoption of FY26 financials and re
Piramal Pharma Critical Care President COO Change
Mr. Jeffrey Hampton, President & COO of Piramal Critical Care, will retire effective 27th November 2026.
Mr. Brian Guy appointed as new President & COO of Piramal Critical Care effective 19th October
Navin Fluorine Q1 FY27 Net Profit Up 108% YoY
Navin Fluorine will hold analyst/investor meets on October 12, 2026, hosted by Goldman Sachs India.
Q1 FY27 consolidated net profit surged 108% YoY to Rs. 243.31 Cr on revenue growth of 44% to Rs. 1,0
Granules India Uploads September 2026 Webinar Recording
Granules India Limited filed a regulatory compliance letter to inform stock exchanges of a webinar recording upload.
The audio recording from the webinar held on September 29, 2026, is now available o
Goyal Urges $100B India-Russia Trade by 2030
Union Minister Piyush Goyal calls for accelerating India-Russia economic partnership to achieve $100B bilateral trade and $50B investment by 2030.
Indian exports to Russia show significant growth: mea
India Aims to Become Global Healthcare Destination
Commerce Minister Piyush Goyal calls for India to become global medical and healthcare hub beyond pharmacy leadership.
India's FTA network expanded from $10T to $60T GDP coverage, with potential $75T
Goyal Urges Resilient Global Healthcare Supply Chains
Commerce Minister Piyush Goyal calls for resilient, globally integrated healthcare supply chains at Bharat Health Global Expo 2026.
India must move beyond generics to R&D leadership in new molecules,
India Invests ₹174 Crore in 210 Nanomedicine Projects
Union Minister Dr. Jitendra Singh announced ₹174 crore funding for 210 nanomedicine R&D projects through the Department of Biotechnology.
India has established regulatory guidelines for nanopharmaceut
Sun Pharma Shareholders Approve Promoter Group Reclassification
Sun Pharma shareholders approved reclassification of certain persons from Promoter Group to Public category on 26 September 2026.
The reclassification was conducted under Regulation 31A of SEBI Listin
Emcure FY26 Revenue Up 16.6% with 33.1% PAT Growth
Emcure reported FY26 revenue of ₹92,035 Mn, up 16.6% YoY, with PAT growing 33.1% to ₹9,413 Mn and margins expanding 120 bps.
The company's India business grew 10% to ₹40,270 Mn with 60%+ chronic mix,
Indegene Digital Summit 2026 Focuses on AI Operationalization
Indegene Limited hosted its eighth Digital Summit focusing on operationalizing AI investments for measurable business outcomes in life sciences.
The summit featured 200+ industry leaders discussing AI
Sun Pharma FY26 Revenue Growth 12% to ₹582 Billion
Sun Pharma reported FY26 revenue of ₹582.2 billion, a 12% YoY growth, with adjusted net profit at ₹124.0 billion.
The company is the 13th largest generics player in the US and maintains its position a
Astonea Labs Submits H1 FY25 Financial Results Rectification
Astonea Labs rectifies BSE filing discrepancy by submitting PDF version of standalone financial results for H1 FY25 ended March 2025.
Company reports ₹5,035.14 lakh total income and ₹321.63 lakh net p
Symbiotec Pharmalab Q1 FY27 Results Post-IPO Listing
Board approved unaudited standalone and consolidated financial results for Q1 FY27 ending June 30, 2026, following recent IPO completion and listing.
Standalone performance showed revenue of ₹2,108.43
Laurus Labs Q1 Net Profit Surges 126%
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Cr, up 29% YoY, with net profit surging 126% to ₹368 Cr.
EBITDA margins expanded 700 bps to 31.8% on strong CDMO growth and operational leverage improvem
Astonea Labs Promoter Ashish Gulati Acquires 14,000 Shares
Astonea Labs Ltd files a voluntary disclosure under SEBI Takeover Regulations for promoter Ashish Gulati's acquisition.
Ashish Gulati, a promoter group member, acquired 14,000 equity shares via open m
Granules India Promoter Sells 1.72 Crore Shares
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares via block deal and open market on September 11, 2026.
Transaction proceeds will fund the second tranche of the company's ongoing p
Senores Pharmaceuticals Reports 108% PAT Growth in FY26
Senores Pharmaceuticals reported consolidated revenue growth of 63% to ₹680 Cr and PAT surge of 108% to ₹122 Cr, driven by regulated markets and portfolio expansion.
The company completed strategic ac
Shamrock Industrial Submits 35th Annual Report for FY26
Shamrock Industrial filed its 35th Annual Report for FY 2025-26, reporting a net loss of ₹108.66 lakhs with zero operational revenue.
The company underwent a complete management change in October 2025
Patron Exim FY26 Net Loss of ₹1.09 Crore
Patron Exim Limited issued its Annual Report and notice for its Fourth AGM to be held on September 30, 2026, via video conference.
The company reported a standalone net loss of ₹108.96 lakh for FY 202
Aarey Drugs 36th AGM Notice and FY26 Results
Aarey Drugs issued notice for its 36th AGM on September 30, 2026, to be held virtually via VC/OAVM with e-voting from September 27-29, 2026.
The company reported FY26 revenue of ₹478.37 crore with net
Panchsheel Organics FY26 Net Profit at ₹10.83 Crore
Panchsheel Organics reported FY26 net profit of ₹10.83 crore on total income of ₹110.30 crore, with recommended final dividend of ₹0.80 per share.
The company convened its 37th AGM on September 30, 20
Alpa Laboratories FY26 Results Decline, AGM Scheduled
Alpa Laboratories reported FY26 revenue decline to ₹12,153 lakhs with net profit falling 29% to ₹1,407 lakhs, reflecting challenging market conditions.
The company convened its 38th AGM on September 3
Concord Drugs FY26 Profit Surges 251% at AGM
Concord Drugs reported 251% net profit growth to ₹1.04 crore and 105% revenue increase to ₹75.85 crore in FY26 standalone results.
The company will hold its 31st AGM on September 30, 2026 to approve f
Navin Fluorine Q1 FY27 Results and Investor Presentation
Navin Fluorine reported strong Q1 FY27 results with revenue up 44% YoY to ₹1,045 Cr and operating EBITDA up 73% YoY to ₹357 Cr.
The company announced analyst/investor meets on September 16-17, 2026 at
Skybiotech Healthcare Limited FY26 Annual Report Submission
Submitted Annual Report for FY 2025-26 to BSE Limited pursuant to SEBI Listing Regulations, including notice of 43rd AGM scheduled for September 30, 2026.
Reported consolidated net loss of ₹111.68 lak
Fabino Enterprises FY26 Loss, AGM, Subsidiary Sale
Fabino Enterprises reported a consolidated net loss of ₹55.87 lakhs for FY26, with revenue of ₹2240.44 lakhs, and proposed its 15th AGM for September 29, 2026.
The notice seeks shareholder approval fo
Kimia Biosciences 33rd AGM Notice and FY26 Results
Kimia Biosciences submitted its 33rd AGM notice and FY25-26 annual report to BSE, with the virtual meeting scheduled for September 28, 2026.
The company reported FY26 revenue of ₹11,488 lakhs and prof
Gujarat Themis Biosyn FY26 PAT ₹46.68 Crores, Major Acquisitions
Gujarat Themis Biosyn reported FY26 total income of ₹168.25 crores with PAT of ₹46.68 crores and declared dividend of ₹0.67 per share.
Company expanded fermentation capacity from 450 KL to 990 KL and
Gufic Biosciences Holds 42nd AGM on September 4
Gufic Biosciences conducted its 42nd Annual General Meeting virtually on September 4, 2026, with 43 shareholders present.
The company declared a final dividend of 10% (₹0.10 per share) for FY2025-26 a
Shree Saibaba Exim Purchases 2.04 Crore Evexia Shares
Evexia Lifecare discloses promoter group entity Shree Saibaba Exim Private Limited purchased 2,03,95,000 equity shares via open market on September 2, 2026.
The acquisition increases Shree Saibaba Exi
Zydus Lifesciences Promoter Group Share Transmission
Zydus Lifesciences discloses off-market transmission of 32,577 shares from late Jasodaben Patel to Prashant Patel.
The disclosure is made under SEBI PIT Regulations regarding promoter group holdings.
Parnax Lab Promoter Acquires 361,872 Shares via Gift
Prakash Shah, a promoter of Parnax Lab, acquired 361,872 equity shares (3.15% stake) from fellow promoter Ila Shah via an off-market gift transfer on July 20, 2026.
The transaction is an inter-se tran
Glenmark Life Sciences Promoter Acquires 44,400 Shares
Glenmark Life Sciences discloses promoter group share acquisitions under SEBI Regulation 30.
Promoter group bought 13,200 shares for ₹14.44 lakh on August 5 and 31,200 shares for ₹35.23 lakh on August
Colinz Labs Open Offer for 26% at ₹54/Share
Mandatory open offer by Annjana Dugar, Likhitta Dugar, Antariksh Dugar and PAC Padam Dugar to acquire up to 6,54,966 shares (26% stake) of Colinz Laboratories Ltd at ₹54 per share, aggregating ₹3.53 c
Novartis AG Sells Entire 70.68% Stake
Novartis AG sold its entire 70.68% holding (1.74 crore shares) in Novartis India Limited on July 29, 2026.
The sale was executed off-market pursuant to a purchase agreement dated February 19, 2026.
No
Novartis AG Sells Entire 70.68% Stake in Novartis India
Novartis AG sold its entire 70.68% stake, comprising 1.74 crore equity shares, in Novartis India Limited.
The off-market transaction was valued at approximately ₹1,376.89 crore and executed on July 29
Bliss GVS Open Offer Addendum Adds Mates Visa as PAC
Bliss GVS Pharma received an addendum to an open offer from Anupam Rasayan, designating Mates Visa Consultancy as a person acting in concert (PAC).
The addendum, dated July 17, 2026, discloses Mates V
WaveRise ChrysCapital Novartis India Open Offer Completion
Axis Capital submits post-offer ad for completed open offer by WaveRise Investments and ChrysCapital for 26% stake in Novartis India.
Open offer acquired 64.19 lakh shares at ₹5,524.97 crore total val